Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

REBECCA · REsearch on BrEast Cancer induced chronic conditions supported by Causal Analysis of multi-source data

H2020Status: CLOSED1 April 202130 September 2025EU funding €5,280,276Call H2020-SC1-BHC-2018-2020

The REBECCA proposal aspires to tap into the potential of Real-world Data (RWD) for supporting groundbreaking clinical research on complex chronic conditions (CCC) as a complement to Randomised Controlled Trials (RCT). REBECCA moves beyond the analysis of Electronic health records (EHR), by combining it with detailed monitoring data from multiple wearable, online behaviour and registry data to monitor patients’ functional, emotional and Quality of Life trajectories, with high temporal granularity. REBECCA also proposes explainable causal modelling combined with deep learning to account for observed and latent confounders in RWD analysis. The project will focus on the complex array of chronic comorbidities developed during breast cancer recovery, in particular studying the impact of primary and adjuvant cancer treatment on patients’ quality of life and assessing the value of detailed patient monitoring as a means for improved patient care, but will also demonstrate the extensibility of REBECCA to other forms of cancer.To this end, a total of seven studies in Sweden, Norway and Spain will produce new knowledge on clinical management of cancer patients that will shape future guidelines and practices for post-cancer treatments. Best practices resulting from the REBECCA studies will be disseminated to researchers, public health and regulatory bodies throughout Europe to facilitate wider adoption of RWD in clinical research. In addition, the REBECCA platform, capable of detailed monitoring and privacy-preserving federated cross-country data analysis, will provide an infrastructure for continued progress on use of RWD beyond the end of the project. Through these activities, REBECCA aims at the mass adoption of RWD for understanding CCCs and ultimately at establishing RWD as a valuable clinical research and patient management tool.

Consortium · 12 organisations

coordinator

ARISTOTELIO PANEPISTIMIO THESSALONIKIS

EL · €827,563

participant

FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA

ES · €466,125

participant

TIMELEX

BE · €213,438

participant

ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS

EL · €410,000

participant

CHAROKOPEIO PANEPISTIMIO

EL · €411,250

participant

HELSE STAVANGER HF

NO · €755,379

participant

EUROPEAN HEALTH MANAGEMENT ASSOCIATION

BE · €243,750

participant

BROSTCANCERFORENINGEN AMAZONA I STOCKHOLMS LAN

SE · €238,125

participant

KAROLINSKA INSTITUTET

SE · €595,086

participant

REGION STOCKHOLM

SE · €291,436

participant

EIGHT BELLS LTD

CY · €221,250

participant

NETCOMPANY S.A.

LU · €606,875

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.